{
    "Trade/Device Name(s)": [
        "ADVIA Centaur\u00ae NT-proBNPII (PBNPII)"
    ],
    "Submitter Information": "Siemens Healthcare Diagnostics Inc.",
    "510(k) Number": "K220265",
    "Predicate Device Reference 510(k) Number(s)": [
        "K072437"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NBC"
    ],
    "Summary Letter Date": "November 18, 2022",
    "Summary Letter Received Date": "November 18, 2022",
    "Submission Date": "September 22, 2023",
    "Regulation Number(s)": [
        "21 CFR 862.1117"
    ],
    "Regulation Name(s)": [
        "B-Type Natriuretic Peptide Test System"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "N-terminal pro-brain natriuretic peptide (NT-proBNP)"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma (EDTA)",
        "Plasma (Lithium heparin)"
    ],
    "Specimen Container(s)": [
        "BD Vacutainer\u00ae SST\u2122 Tube",
        "BD Vacutainer\u00ae RST\u2122 Tube",
        "No gel barrier tube"
    ],
    "Instrument(s)/Platform(s)": [
        "ADVIA Centaur\u00ae XP system"
    ],
    "Method(s)/Technology(ies)": [
        "Chemiluminescence",
        "1-step sandwich immunoassay"
    ],
    "Methodologies": [
        "Immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Calibrator"
    ],
    "Document Summary": "FDA 510(k) summary for Siemens ADVIA Centaur NT-proBNPII assay for quantitative determination of NT-proBNP in serum and plasma using chemiluminescence on ADVIA Centaur XP.",
    "Indications for Use Summary": "Quantitative in vitro diagnostic determination of NT-proBNP in human serum and plasma (EDTA and lithium heparin) as an aid in diagnosis of heart failure in ED and outpatient populations with suspected new onset or worsening heart failure.",
    "fda_folder": "Clinical Chemistry"
}